Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 5/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12176131 | 0.93 | POLB (0.40) | POLBRAB9ANPC1LMNAMAPT | |
| SCHEMBL13060153 | 0.92 | GAA (0.40) | RAB9ANPC1MAPTALDH1A1CNR1 | |
| SCHEMBL13060152 | 0.91 | ALDH1A1 (0.43) | RAB9ANPC1LMNAMAPTALDH1A1 | |
| SCHEMBL12176370 | 0.90 | POLB (0.35) | POLBRAB9ANPC1LMNAMAPT | |
| SCHEMBL3628772 | 0.89 | CCR5 (0.38) | RAB9ALMNAMAPTALDH1A1CCR5 | |
| SCHEMBL3343277 | 0.89 | CCR5 (0.38) | RAB9ALMNAMAPTALDH1A1CCR5 | |
| SCHEMBL24016952 | 0.89 | CNR2 (0.36) | ALDH1A1CCR5CNR1CNR2 | |
| SCHEMBL13060014 | 0.89 | CNR2 (0.36) | ALDH1A1CCR5CNR1CNR2 | |
| SCHEMBL17805423 | 0.89 | ALDH1A1 (0.37) | RAB9ANPC1LMNAMAPTALDH1A1 | |
| SCHEMBL18532714 | 0.89 | CNR2 (0.36) | ALDH1A1CCR5CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102258-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160229802-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-08-11 | — | — | US | disclosed |
| US-9126939-B2 | C5AR antagonists | CHEMOCENTRYX, INC. | 2015-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | POLB 3658/4885RAB9A 2420/4885NPC1 2134/4885 |
| US-20160229802-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | POLB 3658/4885RAB9A 2420/4885NPC1 2134/4885 |
| US-20230102258-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | POLB 3658/4885RAB9A 2420/4885NPC1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.